Barclays PLC Boosts Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Barclays PLC boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 113.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,397 shares of the company's stock after purchasing an additional 66,550 shares during the period. Barclays PLC owned about 0.16% of Viridian Therapeutics worth $2,851,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of VRDN. Arizona State Retirement System increased its stake in shares of Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after acquiring an additional 1,688 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock valued at $318,000 after acquiring an additional 2,036 shares in the last quarter. AlphaCentric Advisors LLC increased its position in shares of Viridian Therapeutics by 20.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company's stock valued at $341,000 after purchasing an additional 2,500 shares during the last quarter. DCF Advisers LLC boosted its stake in Viridian Therapeutics by 22.4% in the second quarter. DCF Advisers LLC now owns 17,750 shares of the company's stock valued at $231,000 after acquiring an additional 3,250 shares during the last quarter. Finally, Quest Partners LLC grew its holdings in Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company's stock valued at $79,000 after purchasing an additional 4,692 shares during the period.

Insider Transactions at Viridian Therapeutics

In related news, CEO Stephen F. Mahoney purchased 21,400 shares of Viridian Therapeutics stock in a transaction dated Friday, September 27th. The stock was purchased at an average cost of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the purchase, the chief executive officer now directly owns 21,400 shares of the company's stock, valued at $499,262. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Thomas W. Beetham acquired 5,000 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the transaction, the chief operating officer now owns 6,000 shares of the company's stock, valued at $140,460. This trade represents a 500.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.65% of the company's stock.

Viridian Therapeutics Stock Down 1.8 %

VRDN stock traded down $0.36 during trading on Wednesday, hitting $19.31. 466,132 shares of the stock traded hands, compared to its average volume of 1,169,970. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -4.48 and a beta of 1.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 1 year low of $11.40 and a 1 year high of $27.20. The firm's 50 day moving average is $21.54 and its two-hundred day moving average is $18.30.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). The firm had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on VRDN. Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Monday, November 25th. BTIG Research upped their price target on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, September 26th. TD Cowen started coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating for the company. Royal Bank of Canada increased their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 17th. Finally, The Goldman Sachs Group upped their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Viridian Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.